Intersection of Polycystic Ovary Syndrome and the Gut Microbiome

被引:68
作者
Rizk, Maryan G. [1 ]
Thackray, Varykina G. [1 ]
机构
[1] Univ Calif San Diego, Dept Obstet Gynecol & Reprod Sci, La Jolla, CA 92093 USA
关键词
polycystic ovary syndrome; hyperandrogenism; insulin resistance; gut microbiome; bile acids; CHAIN FATTY-ACID; BILE-ACIDS; METABOLIC CHARACTERISTICS; INSULIN-RESISTANCE; NUCLEAR RECEPTOR; RAT MODEL; WOMEN; IDENTIFICATION; METFORMIN; LIGANDS;
D O I
10.1210/jendso/bvaa177
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The etiology of polycystic ovary syndrome (PCOS) remains unclear, although studies indicate that both genetic and environmental factors contribute to the syndrome. In 2012, Tremellen and Pearce proposed the idea that dysbiosis of the intestinal (gut) microbiome is a causative factor of metabolic and reproductive manifestations of PCOS. In the past 5 years, studies in both humans and rodent models have demonstrated that changes in the taxonomic composition of gut bacteria are associated with PCOS. Studies have also clearly shown that these changes in gut microbiota are associated with PCOS as opposed to obesity, since these changes are observed in women with PCOS that are both of a normal weight or obese, as well as in adolescent girls with PCOS and obesity compared with body mass index- and age-matched females without the disorder. Additionally, studies in both women with PCOS and rodent models of PCOS demonstrated that hyperandrogenism is associated with gut microbial dysbiosis, indicating that androgens may modulate the gut microbial community in females. One study reported that the fecal microbiome transplantation of stool from women with PCOS or exposure to certain bacteria resulted in a PCOS-like phenotype in mice, while other studies showed that exposure to a healthy gut microbiome, pre/probiotics, or specific gut metabolites resulted in protection from developing PCOS-like traits in mice. Altogether, these results suggest that dysbiosis of the gut microbiome may be sufficient to develop PCOS-like symptoms and that modulation of the gut microbiome may be a potential therapeutic target for PCOS.
引用
收藏
页数:16
相关论文
共 98 条
  • [11] Churchill SJ, 2015, MINERVA GINECOL, V67, P545
  • [12] Cicek M. Nedim, 2003, Archives of Gynecology and Obstetrics, V268, P107
  • [13] Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut
    de la Cuesta-Zuluaga, Jacobo
    Mueller, Noel T.
    Corrales-Agudelo, Vanessa
    Velasquez-Mejia, Eliana P.
    Carmona, Jenny A.
    Abad, Jose M.
    Escobar, Juan S.
    [J]. DIABETES CARE, 2017, 40 (01) : 54 - 62
  • [14] Sex hormone binding globulin - an important biomarker for predicting PCOS risk: A systematic review and meta-analysis
    Deswal, Ritu
    Yadav, Arun
    Dang, Amita Suneja
    [J]. SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE, 2018, 64 (01) : 12 - 24
  • [15] Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications
    Diamanti-Kandarakis, Evanthia
    Dunaif, Andrea
    [J]. ENDOCRINE REVIEWS, 2012, 33 (06) : 981 - 1030
  • [16] Interleukin-22: Immunobiology and Pathology
    Dudakov, Jarrod A.
    Hanash, Alan M.
    van den Brink, Marcel R. M.
    [J]. ANNUAL REVIEW OF IMMUNOLOGY VOL 33, 2015, 33 : 747 - 785
  • [17] The gut microbiome: Relationships with disease and opportunities for therapy
    Durack, Juliana
    Lynch, Susan V.
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2019, 216 (01) : 20 - 40
  • [18] Meta-analysis of gut microbiome studies identifies disease-specific and shared responses
    Duvallet, Claire
    Gibbons, Sean M.
    Gurry, Thomas
    Irizarry, Rafael A.
    Alm, Eric J.
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [19] Eyupoglu ND, 2020, J CLIN ENDOCR METAB, P1
  • [20] Circulating gut microbiota metabolite trimethylamine N-oxide and oral contraceptive use in polycystic ovary syndrome
    Eyupoglu, Nesrin Damla
    Caliskan Guzelce, Ezgi
    Acikgoz, Aylin
    Uyanik, Esra
    Bjorndal, Bodil
    Berge, Rolf K.
    Svardal, Asbjorn
    Yildiz, Bulent Okan
    [J]. CLINICAL ENDOCRINOLOGY, 2019, 91 (06) : 810 - 815